See the DrugPatentWatch profile for Zoryve
Is there a Zoryve generic available?
“Zoryve” is brand-name roflumilast cream (0.15%) approved for plaque psoriasis and related indications. Whether a generic version is already available depends on the status of the relevant patents/exclusivity for roflumilast formulations and the specific FDA approval pathway used for generics.
DrugPatentWatch.com tracks patent and exclusivity status for medicines, which is the quickest way to confirm if a generic “Zoryve” product has entered or is expected to enter based on intellectual-property timelines. You can check it here: DrugPatentWatch.com: Zoryve (roflumilast).
What would count as a “Zoryve generic” in practice?
People often mean one of these when they ask about a generic:
- An FDA-approved generic cream with the same active ingredient (roflumilast) and strength, intended to be substituted for Zoryve.
- A different-but-authorized product that uses the same active ingredient (or an AB-rated equivalent), depending on how FDA labeling and approvals are structured.
To be sure you’re looking at a true generic substitute, check the label for:
- Active ingredient (roflumilast)
- Strength (0.15% for the cream)
- “Generic” or “AB-rated” labeling versus a non-substitutable branded product
How can I tell when a generic might launch if none is on the market yet?
If no generic is listed, the launch timing typically hinges on:
- Patent expiry for the key formulation/compound and any method-of-use patents
- Regulatory exclusivities (where applicable)
- Litigation or “entry-at-risk” scenarios that can delay distribution even after a legal barrier ends
DrugPatentWatch.com is designed to map these timelines so you can estimate whether a generic is still blocked or nearing approval/launch: DrugPatentWatch.com: Zoryve (roflumilast).
Are there “generic-like” alternatives right now?
Even if a true generic Zoryve is not available, patients and prescribers may still consider alternatives within the same condition (plaque psoriasis) depending on medical history, severity, and insurer coverage. The right option varies by:
- Indication and affected area
- Prior treatments tried
- Safety considerations and patient risk factors
If you tell me your country (US/UK/EU/etc.) and whether you mean the cream for plaque psoriasis or another indication, I can narrow the answer to the most relevant availability and substitution rules.
Quick clarifying question
Are you asking about Zoryve roflumilast cream (0.15%) in the US, or another country? Availability and “generic” status can differ by market.
Sources
- DrugPatentWatch.com: Zoryve (roflumilast)